The Shift Toward Flexible Induction Therapy in IBD
For years, the “induction phase” of treating moderately to severely active Crohn’s disease (CD) often required patients to visit clinics for intravenous (IV) infusions. Although effective, this model creates a logistical burden on patients who are already dealing with the unpredictability of a chronic systemic disease.
The industry is now moving toward a more patient-centric approach. By seeking approval for subcutaneous (SC) induction—as seen with the recent application for SKYRIZI (risankizumab-rzaa)—the goal is to provide patients with a choice. Instead of being tethered to an infusion center, patients may soon be able to start their treatment via SC injection.
This transition represents a broader trend in immunology: reducing the friction between the patient and their medication. When induction can be managed via injection, the barrier to starting therapy is lowered, potentially leading to faster intervention and better long-term outcomes.
Precision Immunology: The Rise of Specific IL-23 Blockers
The evolution of Inflammatory Bowel Disease (IBD) treatment is moving away from broad immunosuppression and toward “precision” targeting. SKYRIZI operates as an interleukin (IL)-23 inhibitor, specifically binding to the p19 subunit of the cytokine.
Why does this specificity matter? IL-23 is a key driver in the inflammatory processes linked to several immune-mediated diseases. By selectively blocking this subunit, the therapy aims to dampen the overactive immune response without disabling the entire system. This targeted approach is why the same mechanism is utilized across diverse conditions, including plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
Future trends suggest a deeper dive into these pathways. The success of IL-23 inhibitors suggests that the future of gastroenterology lies in “molecular switches”—medications that can turn off specific inflammatory signals while leaving other vital immune functions intact.
Addressing the “Beyond the Gut” Burden
Crohn’s disease is often discussed in terms of gastrointestinal symptoms like abdominal pain and persistent diarrhea. However, industry experts are increasingly focusing on the systemic and emotional toll of the disease.
Kori Wallace, M.D., Ph.D., vice president and global head of immunology clinical development at AbbVie, notes that “Crohn’s disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reaches beyond the gut as its unpredictability can impact daily life and emotional health for patients.”
The trend in care is shifting toward a holistic model. This includes not only achieving clinical remission—such as the CDAI Clinical Remission (CDAI < 150) targeted in the Phase 3 AFFIRM study—but likewise improving the patient’s economic and emotional quality of life. Reducing the need for hospital visits through SC induction is a direct response to this need for a life “unburdened” by the disease.
Evaluating the Data: The AFFIRM Study Insights
The push for subcutaneous induction is not based on convenience alone, but on rigorous clinical data. The Phase 3 AFFIRM study (NCT06063967) provides a blueprint for how these new dosing regimens are evaluated.
In this global, randomized, double-blind study, 289 patients were evaluated. A critical detail of this study is that 65% of the participants had previously failed advanced therapies. This indicates a trend toward finding solutions for “refractory” patients—those who have tried multiple biologics without success.
The co-primary endpoints—achievement of clinical remission and endoscopic response at week 12—highlight the industry’s insistence on “objective” healing. It is no longer enough for a patient to experience better; the goal is now visible endoscopic improvement of the intestinal lining.
Navigating Safety in Advanced Biologics
As therapies become more potent and targeted, the management of side effects becomes more nuanced. The use of IL-23 inhibitors requires a careful balance of efficacy and safety.
Current safety protocols emphasize the risk of infections, as these medications can lower the immune system’s ability to fight off pathogens. This includes the necessity of screening for tuberculosis (TB) before starting treatment. The potential for serious allergic reactions—including dizziness, swelling, and chest tightness—requires patients to be vigilant.
The future of biologic safety will likely involve more personalized monitoring. For instance, the specific risk of liver problems in patients treated for Crohn’s or ulcerative colitis has led to strict blood-test protocols to detect jaundice or unexplained rashes early.
Frequently Asked Questions
What is the difference between IV and SC induction?
IV (intravenous) induction involves medication delivered through a vein, usually in a clinic. SC (subcutaneous) induction involves an injection under the skin, which offers more flexibility and potential for at-home administration.
How does an IL-23 inhibitor work?
It selectively blocks the p19 subunit of interleukin-23, a cytokine involved in the inflammatory processes that drive diseases like Crohn’s and psoriasis.
What was the purpose of the AFFIRM study?
The AFFIRM study evaluated the efficacy and safety of risankizumab SC as an induction treatment in adults with moderately to severely active Crohn’s disease, including those who had failed previous advanced therapies.
What are the common side effects of SKYRIZI?
In patients with Crohn’s and ulcerative colitis, common side effects include upper respiratory infections, headache, joint pain, stomach pain, and injection site reactions.
Join the Conversation: Do you believe the shift toward at-home subcutaneous induction will significantly change the quality of life for IBD patients? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in immunology and gastroenterology.